Purpose: Uveal melanoma (UM) is the most frequent metastatic ocular tumor in adults. Therapeutic intervention remains ineffective since none of the novel procedures used to treat this disease increased survival rates. To deal with this limitation, additional studies are required to clarify its pathogenesis. The current study focused on describing how epigenetic modulation by miR-142-3p affects changes in some cellular functions underlying UM pathogenesis. Methods and results: Microarray analysis identified 374 miRNAs which were differentially expressed between UM cells and uveal melanocytes. miR-142-3p was one of the 10 most downregulated miRNAs. Quantitative RT-PCR analysis confirmed that miR-142-3p expression levels were significantly decreased in both UM cell lines and clinical specimens. The results of the MTS, clone formation, scratch wound, transwell assays, and in vivo biofluorescence imaging showed that miR-142-3p overexpression significantly inhibited cell proliferation, migration, and invasiveness. Nevertheless, miR-142-3p did not affect cell apoptotic activity or sensitivity to doxorubicin. Cell cycle and EdU analysis showed that miR-142-3p overexpression induced G1/G2 cell cycle arrest and reduced DNA synthesis in UM cells. Microarray analysis showed that miR-142-3p mainly regulates the TGFβ signaling pathway, and those in which MAPK and PI3K-Akt are constituents. Functional interactions between miR-142-3p and CDC25C, TGFβR1, GNAQ, WASL, and RAC1 target genes were confirmed based on the results of the luciferase reporter assay and Western blot analysis. CDC25C or RAC1 downregulation is in agreement with cell cycle arrest and DNA synthesis disorder induction, while downregulation of TGFβR1, GNAQ, WASL, or RAC1 accounts for declines in cell migration. Conclusion: miR-143-3p is a potential therapeutic target to treat UM since overriding its declines in expression that occur in this disease reversed the pathogenesis of this disease. Such insight reveals novel biomarker for decreasing UM vitality and for improved tracking of tumor progression.
Introduction
MicroRNAs (miRNAs) are a group of highly conserved small noncoding RNAs with a length of 21-25 nucleotides. They act on their specific gene targets by translational repression or mRNA cleavage after assembling themselves into an RNA-induced silencing complex (RISC). 1 In 1993, lin-4 became the first discovered miRNA, which was involved in developmental timing regulation in effort is being committed to characterizing miRNA expression profiles because such insight has pinpointed changes reflective of differences in cancer stages, prognosis, and assessment of treatment outcome. 5 Hsa-miR-142-3p, as a member of miRNAs, is involved in the regulation of various physiological activities such as tumorigenesis, 6, 7 cell differentiation, 8 and hematopoiesis. 9 The association between changes in miR-142-3p expression level and tumor size and metastasis has made it possible to use it as a marker of tumorigenesis. 6, 10 Both in vitro and in vivo experiments have revealed that miR-142-3p upregulation can effectively inhibit the proliferation or migration of breast, cervical, and hepatocellular carcinoma cells. [11] [12] [13] Uveal melanoma (UM) is the most frequent intraocular malignancy comprising approximately 3-5% of all melanoma cases. Its incidence varies by sex, race, and country, ranging from 0.31 to 8 per million cases.
14 Even though initially the tumor can be effectively treated with advances in chemotherapy, radiation, and surgical treatment, most patients experience visual loss and more than a third require enucleation. 15 Nevertheless, approximately 40-50% of these patients ultimately develop metastases, which can even occur 10 years after its initial diagnosis. Amongst those individuals who develop liver metastases, their median survival period is only about 6 months. 16 These limitations make it apparent that there is a dire need to develop novel approaches to improve the outcome of UM treatment.
Our previous studies have revealed the important roles of miR-34a, miR-137, and miR-124a in controlling UM pathogenesis by targeting critical oncogenes c-Met or MITF. [17] [18] [19] Our rationale for characterizing the possible role of miR-142-3p in this malignancy stemmed from miRNA microarray analysis showing that miR-142-3p was one of the most downregulated miRNAs in UM cells. This finding coupled with the fact that UM frequently harbors mutation of GNAQ, 20 which is a predicted target gene of miR-142-3p, prompted us to determine if it is another epigenetic modulator of UM development. Here, we provide definitive evidence indicating that declines in miR-142-3p expression levels is an essential factor contributing to the development of numerous phenotypic changes characteristic of UM pathogenesis.
Materials and methods

Cell culture and tumor specimens
Human UM cell line M17 was isolated from a Caucasian patient with primary choroidal melanoma by Dr Dan-Ning Hu at the New York Eye and Ear Infirmary. 21 Another UM cell line, SP6.5, was provided by Dr G. Pelletier (Research Center of Immunology, Quebec, Canada) and was isolated from a Caucasian patient with primary choroidal melanoma. 22 . Following euthanasia and enucleation, the eyes were fixed in methacarn solution for 1 hr at 4°C and dehydrated in an ethanol series and embedded in paraffin. Then, 4-μm thick sections were cut for hematoxylin and eosin staining, and images were collected in conjunction with an upright microscope (BX41; Olympus, Tokyo, Japan). The remaining samples were used for extracting RNA and analyzing the expression levels of miR-142-3p in tumor tissues. All animal treatments were performed in compliance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and approval of the Wenzhou Medical University Animal Care and Use Committee.
Microarray-based miRNA and mRNA expression profiling assay
Total RNA was isolated and purified from UM cell lines (SP6.5 and M17) or uveal melanocytes (D78) using TRIzol reagent. Then, the total RNA was sent to CapitalBio Corporation (Beijing, China) for miRNA expression profiling analysis using CapitalBio Mammalian miRNA Array V 3.0. Data analysis was performed using SpotData Pro software (CapitalBio Corporation). The miRNAs showing statistically significant differences (FDR<0.05) and changes greater than 2-fold were counted as differentially expressed. The total RNA extracted from UM cells transfected with miR-142-3p or NC was sent to Shanghai Biotechnology Corporation (Shanghai, China) for transcriptomic analysis using the gene chip Affymetrix Human U133 Plus 2.0. Raw data were normalized by the MAS 5.0 algorithm in the Affy packages. A scatter plot analysis was used for the statistical analysis, and genes showing statistically significant differences (P<0.05) and changes greater than 2-fold were counted as differentially expressed. The biological functions of the significantly changed mRNAs were examined by gene ontology (GO) analysis. 25 The signaling pathways related to significantly changed mRNAs were analyzed based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. 26 Fisher's exact test was used to classify the GO category and rank the significant signaling pathways, and the false discovery rate (FDR) was calculated to correct the p-values. TargetScanHuman 27 was employed to clarify the identity of differentially expressed genes having several GO-terms and pathway-terms. Those selected were chosen as target genes of miR-142-3p and used to construct a functional network.
Prediction of miR-142-3p target genes
Computational target prediction methods, microarray assay results, and literature reports were used for screening the key targets of miR-142-3p in UM cells. As different prediction tools have their own pros and cons, we utilized multiple tools including TargetScanHuman 27 and miRDB 28 to improve the prediction power.
Luciferase reporter gene assay
The 3' untranslated region (UTR) of target genes was amplified and separately inserted into the miRNA Expression
Reporter Vector (pMIR-REPORT, Ambion). The mutated seed region was generated by a site-directed mutagenesis method as previously described. 29 The primers used in the luciferase reporter assay are provided in Table S3 . HEK293 cells were cotransfected with the firefly luciferase reporter vector, control vector pRL-SV40 containing Renilla luciferase (Promega), and miR-142-3p or the NC with Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific) in 96-well plates. After 24 hrs of transfection, the luciferase activity of each well was detected with the Dual Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. The Renilla luciferase activity was used for transfection normalization.
Western blot analysis
Western blot analysis was performed of harvested cell proteins 48 hrs after initiating transfection. 17, 18 Antibodies against CDC25C, GNAQ, WASL, RAC1, ERK1/2, phospho-ERK1/2, Akt, and phospho-Akt (Ser473) were purchased from Cell Signaling Technology (CST; Beverly, MA, USA), and anti-TGFβR1 antibody was obtained from Santa Cruz Biotechnology (Dallas, TX, USA). GAPDH (CST) was used as a loading control.
Data analysis
All data are expressed as the mean±SEM. Differences between cells transfected with miR-142-3p and NC were analyzed by Student's t-test. A P-value of <0.05 was considered significant. Statistical significance: *P<0.05, **P<0.01, ***P<0.001.
Results
MiRNA profile and marked downregulation of miR-142-3p in UM cells and clinical specimens
To systematically identify differentially expressed miRNAs in UM cells, we performed miRNA microarray analysis of both two UM cell lines and normal uveal melanocytes. The results showed 24 markedly upregulated miRNAs and 350 significantly downregulated miRNAs in UM cells compared to normal uveal melanocytes (Table S4 ). Figure 1A exhibited the 20 most upregulated and downregulated miRNAs between UM cells and uveal melanocytes. MiR-142-3p is among the most downregulated miRNAs. On the other hand, we used TargetScanHuman to predict the potential miRNAs that may target GNAQ ( Figure S1 ). Combined the microarray and bioinformatic analysis, it is evident that miR-142-3p is unique for its expression pattern and the potential to regulate GNAQ. Therefore, such miRNA is an exceptional candidate and thus warrant further investigation.
RT-qPCR was performed to validate if there is an association between tumorigenesis and the miR-142-3p expression levels in the UM cell lines and clinical specimens. It is noteworthy the miR-142-3p levels in the UM cell lines SP6.5 and M17 were approximately 5-fold lower than those in normal uveal melanocytes D78 and um95 (P<0.01, Figure 1B) . Regarding the miR-142-3p expression levels in 20 clinical specimens, they were also significantly lower than those of the normal adjacent uveal tissues (P<0.001, Figure 1C ). These results suggest that UM tumorigenesis is linked to miR-142-3p downregulation.
MiR-142-3p inhibits UM cell proliferation through impeding DNA synthesis and inducing cell cycle G1/G2 arrest To determine if there is an association between changes in miR-142-3p expression levels and UM tumorigenesis, the effect of miR-142-3p transfection into SP6.5 and M17 cells on cell proliferation was determined. The MTS assay results showed that SP6.5 and M17 cell proliferation was suppressed by overexpression of miR-142-3p (Figure 2A ). There was a significant decrease in cell number from day 3 to day 5 in SP6.5 cells (day 5, 30%±1% decrease, P<0.01), and from day 2 to day 5 in M17 cells (day 5, 34%±3% decrease, P<0.01). In addition, overexpression of miR-142-3p significantly reduced colony formation compared to the NC group ( Figure 2B and C) .
Cell cycle analysis revealed that miR-142-3p overexpression increased cell numbers in the G1 and G2 phases accompanied with a corresponding decrease in cells in the S phase ( Figure 2D ). These changes are reflective of declines in cell transition through the G1/S checkpoint. Similarly, DNA synthesis evaluation with the ethynyl-deoxyuridine (EdU) incorporation method showed that ectopic expression of miR-142-3p notably reduced the proportion of cells with newly replicated DNA (EdU-positive cells) compared with the NC (Figure 2E, P<0.01) .
To further assess whether or not increases in apoptosis also accounted for miR-142-3p-mediated declines in cell growth, we carried out Hoechst staining, Annexin-V/PI double-staining, and the caspase 3/7 activity assay. However, changes in apoptosis incidence were not involved because there were no significant differences in nuclear morphology, apoptotic cell ratio, caspase 3/7 activity, or sensitivity to doxorubicin between miR-142-3p transfected cells and their NC counterpart (Figure 3) . Therefore, it is apparent that miR-142-3p upregulation restrains UM cell proliferation through G1/G2 cell cycle arrest, and impeding DNA synthesis, rather than increasing apoptotic activity in UM cells.
MiR-142-3p suppresses UM cell migration and invasion
MiR-142-3p contributions to modulating cell migration and translayer permeation were evaluated based on determining if its upregulation delayed wound closure and translayer cell permeation. The scratch wound assay results indicated that miR-142-3p transfection of UM cells slowed wound closure relative to NC group ( Figure 4A) . Moreover, the number of the miR-142-3p transfected cells migrating to the underside of Transwell chambers decreased in comparison to the NC treated group ( Figure 4B) . Similarly, the miR-142-3p transfected cells displayed diminished invasive capacity relative to the NC cells ( Figure 4C ). Taken together, ectopic miR-142-3p expression hampers both UM cell migratory and invasive activity.
Mir-142-3p inhibits xenograft tumor growth in nude mice bearing UM cells
The in vivo relevance of miR-142-3p modulation was determined by using a suprachoroidal xenograft model in which the effects of miR-142-3p transfected UM cells or its NC were evaluated on their growth rates in the suprachoroidal space of athymic nude mice. After 3 weeks, the tumor size of miR-142-3p overexpressed xenografts was dramatically reduced compared to the NC xenografts ( Figure 5 ). The miR-142-3p expression level was markedly increased in the miR-142-3p transfected xenografts compared to the NC group ( Figure S2 ). Combined with previous in vitro results, our data demonstrated that miR-142-3p plays a suppressor role in UM growth.
Scatter plot analysis and miR-142-3p-target networks based on mRNA expression profiling the irrelevant NC. The transcriptomic analysis data have been deposited in ArrayExpress with accession number E-MTAB-6725. Figure 6A shows the genes whose expression levels changed by a factor greater than two: 782 were upregulated, whereas 545 were downregulated in SP6.5 cells. However, 854 were upregulated and 935 were downregulated in M17 cells, respectively. The results of the KEGG and gene ontology (GO) enrichment analysis indicate that miR-142-3p regulates multiple signaling pathways including MAPK, TGF-beta, Rap1, cGMP-PKG, and PI3K-Akt, and several cellular functions including endocytosis, focal adhesion, actin cytoskeleton, tight junction, and adherens junction ( Figure 6B) . As a validation, we examined two important regulatory constituents of the MAPK and PI3K-Akt pathways, ERK1/2 (MAPK3 and MAPK1) and Akt, by determining corresponding changes in their protein expression levels. Total ERK1/2 and Akt protein levels were unchanged after overexpression of miR-142-3p, but p-ERK1/2 and p-Akt expression levels decreased in both SP6.5 and M17 cells ( Figure 6C) . CDC25C, TGFβR1, GNAQ, WASL, and RAC1 are targets of miR-142-3p
In order to gain insight into the molecular mechanism underlying miR-142-3p function, we selected five candidate target genes of miR-142-3p for further analysis. They were chosen based on in silico prediction methods in combination with microarray assay results. Cell division cycle 25 homolog c (CDC25C), transforming growth factor beta receptor 1 (TGFβR1), guanine nucleotide-binding protein alpha-Q (GNAQ), Wiskott-Aldrich Syndrome like (WASL), and ras-related c3 botulinum toxin substrate 1 (RAC1) were selected as candidates for validation. As shown in Figure S3A , all 3′ UTRs of the target genes possess complementary binding sites for miR-142-3p, and the seed sequence is highly conserved: ACACUAC (A). In order to test if miR-142-3p directly targets these genes, we cloned the 3′ UTRs of each gene into a luciferase reporter vector, exemplified by Figure S3B . The results of the luciferase reporter gene assay demonstrated that transient transfection of miR-142-3p yielded a significant reduction in luciferase activity for all vectors compared with the NC (Figure 7A , P<0.01). Furthermore, mutating the seed sequences in the reporter vectors abolished the interactions between miR-142-3p and 3′ UTRs of the five candidates.
In addition, CDC25C, TGFβR1, GNAQ, and WASL mRNAs in the SP6.5 and M17 UM cell lines were markedly elevated compared with normal uveal melanocytes D78 and um95 ( Figure 7B ). MiR-142-3p overexpression in UM cells significantly reduced the mRNA levels of CDC25C and WASL ( Figure 7C) , and notably reduced the protein levels of CDC25C, TGFβR1, GNAQ, WASL, and RAC1 ( Figure 7D) . Therefore, CDC25C, TGFβR1, GNAQ, WASL, and RAC1 are direct gene targets of miR-142-3p in UM cells. MiR-142-3p targets mediate differential effects on cell proliferation and migration
To confirm the identity of the aforementioned gene targets of miR-142-3p, we determined if their downregulation had the same effect as ectopic expression of this miRNA on responses controlled by these targets in UM cells. As indicated in Figure 8B , appreciable downregulation ( Figure 8A) of the five targets with specific siRNA (GenePharma, Shanghai, China; See Table S5 for a list of siRNA sequences) suppressed proliferation by 42%, 16%, 10%, 17%, and 45%, respectively, in SP6.5 cells, and 22%, 23%, 10%, 16%, and 58%, respectively, in M17 cells. In addition, cell migration was significantly decreased following si-TGFβR1, si-GNAQ, si-WASL, or si-RAC1 transfection ( Figure 8C) . As an important cell cycle-related protein, CDC25C is probably a key target through which miR-142-3p induces G1/G2 cell cycle arrest in UM cells. The results of cell cycle analysis confirmed this conjecture because CDC25C knockdown reduced cell cycle transitions through the G1/S checkpoint. As RAC1 also regulates cell cycle progression, 30 this mode of action exists in UM cells because its knockdown led to G1 phase arrest ( Figure 8D ). In addition, DNA replication declined after transfection with either si-CDC25C or si-RAC1 ( Figure 8E ).
Discussion
Accumulating evidence shows that microRNA dysregulation is closely associated with the occurrence of diseases such as cancer. 31 Thus, clarifying which specific miRNA or miRNA undergo large changes in specific diseases unravels potential biomarkers for improved disease diagnosis and prognosis. Here, we discovered that miR-142-3p was dramatically decreased in both UM cell lines and clinical specimens whereas its overexpression caused G1/ G2 cell cycle arrest and suppressed DNA replication in UM cells. In addition, miR-142-3p downregulation is 
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Relative protein level required for promoting cell migratory and invasive behaviors. Therefore, monitoring changes in miR-142-3p expression levels has the potential to be a biomarker of UM.
Taking into account the in silico results to make predictions based on microarray assays, we chose CDC25C, TGFβR1, GNAQ, WASL, and RAC1 as candidates for further investigation regarding their potential for use in improving management of this very insidious disease.
Each one of these potential candidates that we identified is known to be relevant for supporting cell survival and proliferation. CDC25C is an important cell cycle-related protein that promotes G2/M phase transition by dephosphorylating the mitosis-promoting factor cyclin B/cdk1. 32 CDC25C is reported to be abnormally elevated in lung, breast, and cervical cancer 33 and has a role in regulating DNA replication.
34
TGFβR1 functions as a transducer, delivering extracellular signals controlling gene expression involved in a myriad of functions. This receptor is frequently upregulated in various types of cancer, such as keratoacanthoma, squamous cell carcinoma, oropharyngeal cancer, and cervical cancer. 35, 36 GNAQ is the alpha subunit of GTP binding proteins, which are important modulators or transducers in various transmembrane signaling systems. 37 Changes in GNAQ expression are highly susceptible to UM formation. This is evident because 36-49% of patients presented with GNAQ mutations in a number of studies. 20, 38, 39 WASL mediates the signal from cell surface receptors to the actin cytoskeleton and in turn accelerates the polymerization of actin through activating the ARP2/3 complex. 40 RAC1 is a small GTP-binding protein that regulates actin polymerization. 41 It is involved in mediating lamellipodia protrusion, cell proliferation, and migration. 42, 43 In addition, RAC1 is also involved in the regulation of cell cycle progression. 30 In the current study, we also confirmed that CDC25C, TGFβR1, GNAQ, and WASL mRNA expression was markedly elevated in UM cells. Downregulating CDC25C, TGFβR1, GNAQ, WASL, or RAC1 mimicked the effects of miR-142-3p overexpression which inhibiting UM cell proliferation and/or migration. Knockdown of CDC25C and RAC1 induced cell cycle arrest and impeded DNA synthesis. Our microarray analysis implied that WASL plays multiple roles in the regulation of endocytosis, the actin cytoskeletal structure, and cell junction formation in UM cells. Based on the above information, TGFβR1 and GNAQ act as oncogenes in UM, and CDC25C, WASL, and RAC1 are three very relevant miR-142-3p gene targets holding out a promise for improved therapeutic management in UM. In summary, we have made significant progress towards clarifying the important roles that miR-142-3p plays in regulating UM cellular functions. Our findings indicate that miR-142-3p acts as a tumor suppressor by targeting CDC25C, TGFβR1, GNAQ, WASL, and RAC1. It is conceivable that a strategy to induce miR-142-3p upregulation is potentially a promising avenue for improved clinical management of UM.
